Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Physiol ; 235(5): 4167-4182, 2020 05.
Article in English | MEDLINE | ID: mdl-31709547

ABSTRACT

Osteosarcoma (OS) is one of the most common bone tumors in children and adolescents that cause a high rate of mortality in this age group and tends to be metastatic, in spite of chemotherapy and surgery. The main reason for this can be returned to a small group of malignant cells called cancer stem cells (CSCs). OS-CSCs play a key role in the resistance to treatment and relapse and metastasis through self-renewal and differentiation abilities. In this review, we intend to go through the different aspects of this malignant disease, including the cancer stem cell-phenotype, methods for isolating CSCs, signaling pathways, and molecular markers in this disease, and drugs showing resistance in treatment efforts of OS.


Subject(s)
Bone Neoplasms/therapy , Neoplastic Stem Cells/physiology , Osteosarcoma/therapy , Stem Cell Transplantation/methods , Biomarkers, Tumor , Gene Expression Regulation, Neoplastic , Humans
2.
Biomed Pharmacother ; 111: 873-881, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30841466

ABSTRACT

Today, cancer is one of the most common causes of death. Osteosarcoma (OS) is a tumor in long bones and its prevalence is high in teenagers and young people. Among the methods that used to treat cancer, one can name chemotherapy, surgery, and radiotherapy. Since these methods have some disadvantages and they are not absolutely successful, the use of microRNAs (miRNAs) is very useful in diagnosis and treatment of OS. MiRNAs are small non-coding RNA molecules, containing 18-25 nucleotides, which are involved in the regulation of gene expression via binding to messenger RNA (mRNA). These RNAs are divided into two classes of suppressors and oncogenes. During OS, there is aberrant expression of several miRNAs. Among these miRNAs are downregulation of miR-193 that has been associated with cancer occurrence. The aim of the current manuscript is to have overview on the treatment approaches of OS with special focus on miR-193.


Subject(s)
Bone Neoplasms/genetics , MicroRNAs/genetics , Osteosarcoma/genetics , Down-Regulation/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , RNA, Messenger/genetics
3.
J Cell Biochem ; 120(4): 4783-4793, 2019 04.
Article in English | MEDLINE | ID: mdl-30450580

ABSTRACT

Osteosarcoma (OS) is the most common primary malignant tumor of the bone with a strong tendency to early metastasis, and occurs in growing bones more commonly in children and adolescents. Considering the limited therapeutic methods and lack of 100% success of these methods, developing innovative therapies with high efficacy and lower side effects is needed. Meanwhile, miRNAs and the studies indicating the involvement of miRNAs in OS development have attracted attentions as a result of the frequent abnormalities in expression of miRNAs in cancer. miRNAs are noncoding short sequences with lengths ranging from 18 to 25 nucleotides that play a very important role in cellular processes, such as proliferation, differentiation, migration, and apoptosis. MiRNAs can have either oncogenic or tumor suppressive role based on cellular function and targets. This review aimed to have overview on miR-142 as a tumor suppressor in OS. Moreover, the genes involved in the disease, such as RAC1, HMAG1, MMP9, MMP2, and E-cadherin, which have irregularities as a result of change in miR-142 expression, and, thereby, result in increasing the proliferation, invasion, and metastasis of the cells in the tissues and OS cells will be discussed.


Subject(s)
Bone Neoplasms/genetics , MicroRNAs/genetics , Osteosarcoma/genetics , Adolescent , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Child , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Humans , MicroRNAs/metabolism , Osteosarcoma/metabolism , Osteosarcoma/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...